Literature DB >> 4183907

Infantile cortical hyperostosis associated with thrombocythaemia.

D Pickering, B Cuddigan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4183907     DOI: 10.1016/s0140-6736(69)90168-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Raised immunoglobulin levels and thrombocytosis in infantile cortical hyperostosis.

Authors:  I J Temperley; S J Douglas; J P Rees
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

2.  Infantile cortical hyperostosis associated with the Wiskott-Aldrich syndrome.

Authors:  M Abinun; M Mikuska; B Filipović
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

3.  Vitamin E deficiency and thrombocytosis in Caffey's disease.

Authors:  B R Keeton
Journal:  Arch Dis Child       Date:  1976-05       Impact factor: 3.791

4.  Mineral balance in infantile cortical hyperostosis: effects of corticosteroids.

Authors:  D G Barr; N R Belton
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

5.  Wiskott-Aldrich syndrome associated with idiopathic infantile cortical hyperostosis (Caffey's disease).

Authors:  G McEnery; F W Nash
Journal:  Arch Dis Child       Date:  1973-10       Impact factor: 3.791

6.  Infantile cortical hyperostosis with raised immunoglobulins.

Authors:  V Ramchander; R Ramkissoon
Journal:  Arch Dis Child       Date:  1978-05       Impact factor: 3.791

7.  The c.3040C > T mutation in COL1A1 is recurrent in Korean patients with infantile cortical hyperostosis (Caffey disease).

Authors:  Tae-Joon Cho; Hyuk Ju Moon; Dae-Yeon Cho; Moon Seok Park; Dong Yeon Lee; Won Joon Yoo; Chin Youb Chung; In Ho Choi
Journal:  J Hum Genet       Date:  2008-08-13       Impact factor: 3.172

8.  Caffey disease with raised immunoglobulin levels and thrombocytosis.

Authors:  T Sathish Kumar; Julius Xavier Scott; Leni Grace Mathew
Journal:  Indian J Pediatr       Date:  2008-02       Impact factor: 1.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.